… highest LOE for the prediction of more aggressive prostate cancer and could help clinicians
to manage patients with localised prostate cancer. The other biomarkers show a potential …

… has not proven useful for prostate cancer until late in the natural history of the disease. …
active surveillance, patients with localized prostate cancer are usually treated with definitive …

… review summarizes advances in prostate cancer diagnosis and treatment. Screening for
prostate cancer has been reviewed … of patients with a normal prostate cancer antigen 3 test have …

… localized prostate cancer owing to limited life expectancy, comorbidity, and the prolonged
natural history of the prostate cancer … -risk prostate cancer according to their personal opinion. …

… Despite radical treatment for clinically localized prostate cancer (PCa) with curative intent, …
of the primary tumor [1], [2], [3]. PCa recurrence is usually first suspected when a rise in serum …

… for the systematic review. The Oncotype Dx … natural history to provide perspective regarding
the tradeoff between treatment-related side effects and the likelihood of disease progression. …

… The long natural history of localised prostate cancer poses challenges in clinical trials designed
to improve overall survival. Moreover, the length of follow-up needed in therapeutic trials …

… available treatments for localized prostate cancer were surgery, … Prostate cancer is a disease
of long natural history. Patients … Peer-review: This manuscript was prepared by the invitation …

… Men newly diagnosed with localized prostate cancer (LPC) are facing difficult decisions
regarding treatment. They need to choose from a range of treatment options (eg, surgery, …

… We grouped outcomes by time point of measurement (eg, 3–5 years after test measurement
vs 6–10 years) due to the current understanding of the natural history of prostate cancer. For …